Recombinant human CTLA4 protein

Cat No.
ATGP3914

Size

QTY

List Price

10ug

USD 60


20ug

USD 90

50ug

USD 150

100ug

USD 170

250ug

USD 220

500ug

USD 380

1mg

USD 630

USD 0



Product Information

Product Type
Recombinant Protein
Expression System
Baculovirus
Domain
36-161aa
UniProt No.
P16410
NCBI Accession No.
NP_005205
Alternative names
Cytotoxic T-lymphocyte protein 4 isoform CTLA4-TM precursor, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4, CD152, CELIAC3, Celiac disease 3, Insulin-dependent diabetes mellitus 12, IDDM12, CD, GSE
Additional Information
ATGP3364 has been replaced with a catalog number ATGP3914.

Product Specification

Molecular Weight
40.8 kDa (368aa)
Concentration
0.5mg/ml (determined by absorbance at 280nm)
Formulation
Liquid in. Phosphate-Buffered Saline (pH 7.4) containing 10% glycerol
Purity
> 95% by SDS-PAGE
Bioactivity
The activity is determined by the IL-2 ELISA in a using Jurkat human acute T cell leukemia cells. The ED50 range ≤150ng/ml with Human B7 1/CD80.
Endotoxin
< 1 EU per 1ug of protein (determined by LAL method)
Tag
hIgG-His-Tag
Applications
SDS-PAGE, Bioactivity
Storage
Can be stored at +2C to +8C for 1 week. For long term storage, aliquot and store at -20C to -80C. Avoid repeated freezing and thawing cycles.

Data

SDS-PAGE

3ug by SDS-PAGE under reducing condition and visualized by coomassie blue stain.

Biological Activity

Human CTLA-4 inhibits Human B7 1/CD80 induced IL-2 secretion of the Jurkat human acute T cell leukemia cells. The ED50 range ≤150 ng/ml.

Note: For research use only. This product is not intended or approved for human, diagnostics or veterinary use.